Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00978120 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 390
- Enrollment target
NCT00978120 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 390 participants.
The verdict
NCT00978120, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in people with asthma. The study will enroll 350, and possibly up to 400 healthy adults ages 12 and older with mild, moderate, or severe asthma. Participants will be randomly assigned to 1 of 2 possible vaccine groups: group 1 will receive 15 mcg of H1N1 vaccine; group 2 will receive 30 mcg of H1N1 vaccine given as two 15 mcg injections. Both groups will receive vaccine injections on days 0 and 21. Study procedures include: medical history, physical exam, spirometry, maintaining a memory aid and, and blood sample collection. Participants will be involved in study related procedures for approximately 7 months.
Interventions
- BIOLOGICAL H1N1 vaccine high dose
- BIOLOGICAL H1N1 vaccine low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00978120
The ClinicalTrials.gov registry entry for NCT00978120 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which H1N1 vaccine high dose is the first listed.
NCT00978120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00978120 about?
NCT00978120 is a clinical study titled "Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma". The purpose of this study is to assess the safety and the body's immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in people with asthma. The study will enroll 350, and possibly up to 400 healthy adults ages 12 and older with mild, moderate, or severe asthma....
What is the current status of trial NCT00978120?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 390 participants. The study started on 2009-10. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00978120?
The interventions under investigation include: H1N1 vaccine high dose (BIOLOGICAL), H1N1 vaccine low dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT00978120?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.